The ubiquitin-proteasome system as a molecular target in solid tumors: An update on bortezomib

A. Milano, F. Perri, Francesco Caponigro

Research output: Contribution to journalArticle

Abstract

The ubiquitin-proteasome system has become a promising molecular target in cancer therapy due to its critical role in cellular protein degradation, interaction with cell cycle and apoptosis regulation, and unique mechanism of action. Bortezomib (PS-341) is a potent and specific reversible proteasome inhibitor, which has shown strong in vitro antitumor activity as single agent and in combination with other cytotoxic drugs in a broad spectrum of hematological and solid malignancies. In preclinical studies, bortezomib induced apoptosis of malignant cells through the inhibition of NF-κB and stabilization of pro-apoptotic proteins. Bortezomib also promotes chemo- and radiosensitization of malignant cells in vitro and inhibits tumor growth in murine xenograft models. The proteasome has been established as a relevant target in hematologic malignancies and bortezomib has been approved for the treatment of multiple myeloma. This review summarizes recent data from clinical trials in solid tumors.

Original languageEnglish
Pages (from-to)171-178
Number of pages8
JournalOncoTargets and Therapy
Volume2
Publication statusPublished - 2009

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Hematologic Neoplasms
Neoplasms
Apoptosis
Apoptosis Regulatory Proteins
Proteasome Inhibitors
Multiple Myeloma
Heterografts
Proteolysis
Cell Cycle
Bortezomib
Clinical Trials
Growth
Pharmaceutical Preparations
In Vitro Techniques

Keywords

  • Bortezomib
  • Clinical studies
  • NF-κB
  • Proteasome
  • Solid tumors

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

The ubiquitin-proteasome system as a molecular target in solid tumors : An update on bortezomib. / Milano, A.; Perri, F.; Caponigro, Francesco.

In: OncoTargets and Therapy, Vol. 2, 2009, p. 171-178.

Research output: Contribution to journalArticle

@article{97b59cc2ebe94fd5bdb368b50c0cf3e6,
title = "The ubiquitin-proteasome system as a molecular target in solid tumors: An update on bortezomib",
abstract = "The ubiquitin-proteasome system has become a promising molecular target in cancer therapy due to its critical role in cellular protein degradation, interaction with cell cycle and apoptosis regulation, and unique mechanism of action. Bortezomib (PS-341) is a potent and specific reversible proteasome inhibitor, which has shown strong in vitro antitumor activity as single agent and in combination with other cytotoxic drugs in a broad spectrum of hematological and solid malignancies. In preclinical studies, bortezomib induced apoptosis of malignant cells through the inhibition of NF-κB and stabilization of pro-apoptotic proteins. Bortezomib also promotes chemo- and radiosensitization of malignant cells in vitro and inhibits tumor growth in murine xenograft models. The proteasome has been established as a relevant target in hematologic malignancies and bortezomib has been approved for the treatment of multiple myeloma. This review summarizes recent data from clinical trials in solid tumors.",
keywords = "Bortezomib, Clinical studies, NF-κB, Proteasome, Solid tumors",
author = "A. Milano and F. Perri and Francesco Caponigro",
year = "2009",
language = "English",
volume = "2",
pages = "171--178",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The ubiquitin-proteasome system as a molecular target in solid tumors

T2 - An update on bortezomib

AU - Milano, A.

AU - Perri, F.

AU - Caponigro, Francesco

PY - 2009

Y1 - 2009

N2 - The ubiquitin-proteasome system has become a promising molecular target in cancer therapy due to its critical role in cellular protein degradation, interaction with cell cycle and apoptosis regulation, and unique mechanism of action. Bortezomib (PS-341) is a potent and specific reversible proteasome inhibitor, which has shown strong in vitro antitumor activity as single agent and in combination with other cytotoxic drugs in a broad spectrum of hematological and solid malignancies. In preclinical studies, bortezomib induced apoptosis of malignant cells through the inhibition of NF-κB and stabilization of pro-apoptotic proteins. Bortezomib also promotes chemo- and radiosensitization of malignant cells in vitro and inhibits tumor growth in murine xenograft models. The proteasome has been established as a relevant target in hematologic malignancies and bortezomib has been approved for the treatment of multiple myeloma. This review summarizes recent data from clinical trials in solid tumors.

AB - The ubiquitin-proteasome system has become a promising molecular target in cancer therapy due to its critical role in cellular protein degradation, interaction with cell cycle and apoptosis regulation, and unique mechanism of action. Bortezomib (PS-341) is a potent and specific reversible proteasome inhibitor, which has shown strong in vitro antitumor activity as single agent and in combination with other cytotoxic drugs in a broad spectrum of hematological and solid malignancies. In preclinical studies, bortezomib induced apoptosis of malignant cells through the inhibition of NF-κB and stabilization of pro-apoptotic proteins. Bortezomib also promotes chemo- and radiosensitization of malignant cells in vitro and inhibits tumor growth in murine xenograft models. The proteasome has been established as a relevant target in hematologic malignancies and bortezomib has been approved for the treatment of multiple myeloma. This review summarizes recent data from clinical trials in solid tumors.

KW - Bortezomib

KW - Clinical studies

KW - NF-κB

KW - Proteasome

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=77953415635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953415635&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77953415635

VL - 2

SP - 171

EP - 178

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -